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ABSTRACT 51 
OBJECTIVE: To evaluate the clinical utility of a quantitative deep-learning derived vascular 52 
severity score for retinopathy of prematurity (ROP) by assessing its correlation with clinical 53 
ROP diagnosis and by measuring clinician agreement in applying a novel scale.   54 
DESIGN: Analysis of existing database of posterior pole fundus images and corresponding 55 
ophthalmoscopic examinations using two methods of assigning a quantitative scale to vascular 56 
severity. 57 
SUBJECTS AND PARTICIPANTS: Images were from clinical exams of patients in the 58 
Imaging & Informatics in ROP consortium. 4 ophthalmologists and 1 study coordinator 59 
evaluated vascular severity on a 1-9 scale. 60 
METHODS: A quantitative vascular severity score (1-9) was applied to each image using a 61 
deep learning algorithm. A database of 499 images was developed for assessment of inter-62 
observer agreement. 63 
MAIN OUTCOME MEASURES: Distribution of deep learning derived vascular severity 64 
scores with the clinical assessment of zone (I,II,III), stage (0,1,2,3) and extent (<3, 3-6, >6 clock 65 
hours) of stage 3 evaluated using multivariable linear regression. Weighted kappa and Pearson 66 
correlation coefficients for inter-observer agreement on 1-9 vascular severity scale. 67 
RESULTS: For deep learning analysis, a total of 6344 clinical examinations were analyzed. A 68 
higher deep learning derived vascular severity score was associated with more posterior disease, 69 
higher disease stage, and higher extent of stage 3 disease (P<.001 for all). For a given ROP stage, 70 
the vascular severity score was higher in zone I than zone II or III (P<.001). For a given number 71 
of clock hours of stage 3, the severity score was higher in zone I than zone II (P=.03 in zone I 72 
and P<.001 in zone II). Multivariable regression found zone, stage, and extent were all 73 
independently associated with the severity score (P<.001 for all). For inter-observer agreement, 74 
mean (±Standard Deviation [SD]) weighted kappa was 0.67 (±0.06) and Pearson Correlation 75 
coefficient (±SD) was 0.88 (±.04) on the use of a 1-9 vascular severity scale. 76 
CONCLUSIONS: A vascular severity scale for ROP appears feasible for clinical adoption, 77 
corresponds with current international classification of ROP severity, and facilitates the use of 78 
objective technology such as deep learning to improve consistency of ROP diagnosis.  79 
  80 
INTRODUCTION 81 
Plus disease has been a marker of severe retinopathy of prematurity (ROP) since prior to 82 
the development of the International Classification of ROP (ICROP) in the 1980s and has been 83 
an essential component of treatment decisions since the Multicenter Trial for Cryotherapy for 84 
ROP (CRYO-ROP) study.1-3 CRYO-ROP demonstrated improved outcomes with treatment of 85 
threshold disease, defined as 5 continuous or 8 discontinuous clock hours of stage 3 ROP with 86 
plus disease, which was defined based on a standard photograph. Subsequently, the Early 87 
Treatment for ROP (ET-ROP) study supported revised treatment criteria for any eye with stage 3 88 
in zone 1, or any extent and stage with plus disease.4 This had the effect of removing a 89 
quantitative variable (extent of stage 3 disease) from the assessment of disease severity in ROP 90 
and replacing treatment decisions primarily with qualitative assessment of the anterior-posterior 91 
location of stage 3 disease, and the presence or absence of plus disease. 92 
In many domains of medicine, technological advancements have led to a transition from 93 
qualitative and subjective assessment of disease severity to quantitative and objective measures 94 
of disease. In ophthalmology, for example, the development of optical coherence tomography 95 
(OCT) has led to clinical trial and treatment paradigms that increasingly rely on objective, 96 
quantitative measures rather than qualitative examination features. In terms of ROP, it is well 97 
established that there is significant inter-observer variability in all components of clinical 98 
diagnosis (zone, stage, plus disease), and growing evidence that this leads to real-world treatment 99 
variability.5-10 For plus disease, it has been established that systematic bias between experts is a 100 
key source of diagnostic discrepancy along the continuum of disease severity.11,12 To this end, an 101 
objective metric of ROP disease severity might improve diagnostic agreement and facilitate 102 
future clinical trials designed to improve visual and anatomic outcomes in ROP.  103 
Deep learning in medicine has gained prominence as an artificial intelligence 104 
methodology with potential for extremely accurate image-based disease classification. We have 105 
previously demonstrated that a deep learning approach can diagnose plus disease as well as ROP 106 
experts, and subsequent work has demonstrated that this technology may be used to develop a 107 
continuous vascular severity score to quantify disease severity objectively.13-16 However, there is 108 
a gap in knowledge regarding how a vascular severity score may integrate into the current ROP 109 
classification schema with zone, stage, and plus disease. Moreover, it is unclear whether 110 
increasing the granularity of “plus disease” along a continuum might worsen, rather than 111 
improve, diagnostic agreement.  112 
In this study, we aimed to evaluate the relationship between a deep learning-derived 113 
vascular severity scale with zone, stage, extent of stage 3, and plus disease, and determine 114 
whether human graders may be able to adapt and utilize such as system. We feel this approach 115 
will have significant benefits for ROP care, and that it may be generalized to other ophthalmic 116 
diseases using deep learning methods. 117 
METHODS 118 
This study was conducted as part of a multicenter ROP cohort study by the Imaging and 119 
Informatics in ROP (i-ROP) consortium. This study was approved by the Institutional Review 120 
Board at the coordinating center (Oregon Health & Science University) and at each of 8 study 121 
centers (Columbia University, University of Illinois at Chicago, William Beaumont Hospital, 122 
Children’s Hospital Los Angeles, Cedars-Sinai Medical Center, University of Miami, Weill 123 
Cornell Medical Center, Asociacion para Evitar la Ceguera en Mexico [APEC]). This study was 124 
conducted in accordance with the Declaration of Helsinki. Written informed consent for the 125 
study was obtained from parents of all infants enrolled in this study.  126 
Datasets 127 
Deidentified images from clinical examinations performed between July 2011 and 128 
December 2016 were assessed. All images were obtained using a commercially available camera 129 
(RetCam; Natus Medical Incorporated, Pleasanton, CA). Each study eye examination was 130 
assigned a reference standard diagnosis (RSD) for all combinations of zone, stage, and plus 131 
disease. The RSD was determined using methods previously published. 17In brief, the reference 132 
standard was based on a consensus diagnosis between the ophthalmoscopic grading and 3 133 
independent image-based diagnoses on the full ICROP classification including zone, stage, and 134 
plus. The dataset (ICROP comparison dataset) also included the extent of stage 3 disease 135 
(number of clock hours) as determined by ophthalmoscopy when stage 3 was diagnosed. Images 136 
of stage 4 and higher were excluded. A subset of this dataset (499 images) was set aside for 137 
reliability analysis (inter-observer agreement dataset). 138 
Description of the clinician-assigned vascular severity score 139 
We defined a scale from 1-9 to represent a spectrum of vascular abnormality. The labels 140 
1-3 were applied when the image fell into the no plus category (with 1 reflecting very thin and 141 
straight vessels and 3 reflecting some vascular abnormality but insufficient for pre-plus disease). 142 
Similarly, 4-6 broadly reflected the range of pre-plus, and 7-9 reflected the range of disease 143 
where the majority of examiners would diagnose plus disease.  144 
Reliability Analysis  145 
Five trained graders (4 ophthalmologists experienced in ROP and 1 non-physician 146 
experienced in review of ROP images) independently graded the 499 images as 1 to 9 using this 147 
conceptual framework. To evaluate inter-observer agreement, we calculated weighted kappa and 148 
Pearson correlation coefficients for each pair of graders. Kappa values were interpreted using a 149 
commonly-accepted scale: 0 to 0.20, slight agreement; 0.21 to 0.40, fair agreement; 0.41 to 0.60, 150 
moderate agreement; 0.61 to 0.80, substantial agreement; and 0.81 to 1.00, near-perfect 151 
agreement. 152 
Comparison of deep learning-derived score with ICROP classification 153 
The i-ROP deep learning system was used to classify the probability of an image having 154 
an associated reference standard diagnosis of plus disease on a 3-level scale (normal, preplus, 155 
plus) for each image in the ICROP comparison dataset. An automated ROP vascular severity 156 
score was then assigned to each image, from 1 (very thin and smooth vessels) to 9 (severe plus 157 
disease) using methods previously published based on the probabilities of each disease category: 158 
(1 × probability of normal) + (5 × probability of pre-plus disease) + (9 × probability of plus 159 
disease).14,15,18  160 
We compared the quantitative vascular severity score (1-9) as a function of all ICROP 161 
components as determined by the reference standard diagnosis of plus (plus, pre-plus, or no plus), 162 
stage (0, 1, 2, 3) and as a function of number of quadrants with stage 3 disease (< 3 clock hours, 163 
between 3-6 clock hours, or > 6 clock hours), in zone I, II and III. Comparisons were done using 164 
analysis of variance (ANOVA) in Stata v15 (College Station, TX). We then performed 165 
multivariable linear regression comparing the 1-9 output as a function of zone, stage, and extent 166 
as above.  167 
RESULTS 168 
Evaluation of a deep learning derived vascular severity score. 169 
Using the full ICROP comparison dataset, we were able to evaluate relationships between 170 
the deep learning-derived vascular severity score and the ICROP classification for 6344 eye 171 
examinations. Table 1 displays the demographics of the dataset and the ICROP sub-172 
classifications for all exams in the ICROP comparison dataset.  173 
Figure 2 demonstrates the median (interquartile range [IQR]) vascular severity score for 174 
all images by RSD for plus disease on the left panel. Images had a median value of 1.2 (1.0-2.3) 175 
for no plus, 5.1 (4.6-6.0) for pre-plus, and 8.8 (8.2 – 9.0) for plus disease (P<0.01). In the middle 176 
panel, Figure 2 demonstrates the median and IQR for the vascular severity score as a function of 177 
stage (0, 1, 2, 3) in each zone (I, II, III).  The vascular severity score as associated with 178 
increasing stage of disease in zone I (left, P<.001), zone II (middle, P<.001), and zone III (right, 179 
P<.001), and the vascular severity score for stage 1, 2 and 3 was higher in Zone I than the 180 
corresponding score for the same stage of disease in zone II (P<.001). On the right, Figure 2 181 
demonstrates the same relationship with the extent of stage 3 disease. The vascular severity score 182 
was associated with a higher number of clock hours of stage 3 disease in both zone I and II 183 
(P=0.03 in zone I and P<.001 in zone II), and was higher in zone I than zone II for the same 184 
number of clock hours (P<.001).  Multivariable regression found zone, stage, and extent were all 185 
independently associated with the 1-9 score (P<0.001 for all dependent variables). 186 
Reliability Analysis 187 
The distribution of disease severity for the inter-observer agreement dataset is shown in 188 
Table 1.  The mean (± standard deviation [SD]) 1-9 score applied to images with an RSD of no 189 
plus disease was 2.4 (± 0.8) for no plus disease, 4.7 (±1.1) for pre-plus, and 7.7 (±1.0) for plus 190 
disease (P<.001). Table 2 displays the relationship between the median 1-9 score assigned to 191 
each of the 499 images by the 5 graders versus the plus disease reference standard, 192 
demonstrating the transition from no plus to pre-plus between 3 and 4, and from pre-plus to plus 193 
between 6 and 7.  194 
Table 3 reports the weighted kappa as well as the Pearson correlation coefficient for each 195 
examiner relative to each other. Kappa statistics showed that 9 of 10 paired comparisons showed 196 
strong agreement (kappa between 0.6 and 0.8) with a mean (+SD]) weighted kappa was 0.67 197 
(+0.06). Mean Pearson correlation coefficient (+SD) was 0.88 (+.04) with all pairs of graders 198 
demonstrating high correlation (r > 0.8).  199 
DISCUSSION 200 
Retinal vascular changes in retinopathy of prematurity run a continuum from very mild to 201 
very severe. In the original ICROP, these changes were grouped into two categories: plus or no 202 
plus.19 In the ICROP revisited paper in 2005, an intermediate pre-plus category was added.1 In 203 
this paper, we propose expanding the ordinal categories to a more granular scale from 1-9, 204 
present two different methods for developing and validating such a scale, and demonstrate the 205 
relationship between the 1-9 scale and the conventional zone, stage, and plus disease 206 
classifications in ICROP. The key findings are: 1) A higher deep learning-derived vascular 207 
severity score was associated with indicators of more severe disease in the current ICROP 208 
classification such as more posterior zone, higher maximum stage, and higher extent of stage 3 209 
disease. 2) Expert graders agreed on both absolute and relative 1-9 scores with moderate to high 210 
agreement.  211 
These results highlight that although ICROP defined independent classifications for zone, 212 
stage, and plus disease, these categories are not physiologically independent. Instead, the 213 
underlying disease phenotypes reflect a spectrum of disease, which is reflected in changes in the 214 
vascular severity in the posterior pole. The zone of disease represents the area of vascularized 215 
retina, which correlates with the number of capillary beds between the central retinal artery and 216 
vein, and inversely with the area of avascular retina. The stage of disease represents the degree of 217 
disrupted vasculogenesis and extraretinal neovascularization at the border, which varies both in 218 
degree and extent for up to 12 clock hours, and which presumably leads to vascular shunting that 219 
increases total retinal blood flow. It is interesting to speculate how total retinal blood flow, the 220 
role of shunt vessels and intravascular resistance in large and small blood vessels might be 221 
related these changes in the posterior pole retinal vessels; however, these parameters are difficult 222 
to measure in vivo. The development of better tools to quantify retinal blood flow and the micro- 223 
and macro-vascular changes of retinal blood vessels in ROP, such as OCT angiography, 20 may 224 
help better elucidate these underlying mechanisms, and improve our understanding of ROP 225 
pathophysiology.   226 
Further, results from this study demonstrate that clinicians may be able to recognize these 227 
subtle changes in vascular abnormality that correlate with changes in overall ROP severity. In 228 
some cases, these changes in posterior pole dilation and tortuosity can be appreciated, but are not 229 
captured in the current plus disease classification (Figure 3). One advantage of a quantitative 1-9 230 
scale applied clinically is that it may improve recognition of disease progression, even in the 231 
absence of photography and image analysis. Previous work has demonstrated that this deep 232 
learning-derived scale could be used to monitor disease progression, and disease regression after 233 
treatment, over time and provide benefits with regard to prediction of disease worsening or 234 
improvement.14,15 In other words, whether applied subjectively by a clinician, or objectively by a 235 
deep learning system, documentation of vascular severity on a more granular level may facilitate 236 
earlier recognition and referral of worsening disease.  237 
Another advantage of a quantitative 1-9 scale is that it separates the assessment of 238 
relative vascular severity from the treatment implications of a diagnosis of plus disease. That is, 239 
assessment of “plus disease” carries the connotation of “this baby needs to be treated” given 240 
current evidence-based treatment guidelines. In contrast, the diagnosis of a “7” simply implies 241 
that the vascular severity is more severe than a “6.” Previous work has demonstrated that 242 
clinicians are much more likely to agree on relative disease severity than on labels of plus 243 
disease, perhaps in part for this reason.12,21 Although there are published evidence-based 244 
treatment criteria based on standard photographs for plus disease, it is well recognized that 245 
subjective cognitive processes affect perception of disease severity. In particular: 1) Despite the 246 
presence of a standard photograph, in research studies experts identify widely varying degrees of 247 
vascular abnormality as plus disease, with one study demonstrating some experts diagnose up to 248 
6 times as many babies with plus disease compared to others.11 2) In clinical trials, differences in 249 
diagnosis of treatment-requiring ROP have been found to be due to plus disease diagnostic 250 
differences among physicians in different geographic regions, suggesting a training bias.10,22 3) 251 
When asked to explain clinical reasoning, experts often cite different phenotypic features when 252 
arriving at disparate diagnoses.23 4) In analysis of inter-observer discrepancies, pairs of experts 253 
were more likely to disagree on the diagnosis of plus if they also differ on the diagnosis of stage, 254 
suggesting that perception of vascular severity is influenced by assessment of peripheral 255 
pathology.5 5) Experts are more likely to diagnose plus disease if the pre-test probability for 256 
severe disease is higher based on demographics; that is, they are more likely to see plus disease if 257 
they believe that ought to be more likely to see plus disease.24 All of these issues could be 258 
addressed with objective assessment of vascular severity. 259 
The therapeutic implications of this proposed vascular severity score must be evaluated 260 
prospectively and carefully. Either through clinical adoption of standard images reflecting a 261 
wider range of vascular severity or through the use of deep learning, or both, prospective 262 
evaluation of clinical trial data may help elucidate the “right” level of vascular severity to label 263 
plus disease and continue to use evidence-based criteria to guide treatment. Alternatively, it may 264 
reveal that other combinations of zone, stage, and extent are as or more important than the 265 
absolute level of vascular severity in the posterior pole. These results suggest that, on average, a 266 
zone II eye, especially in anterior zone II, would need either a higher stage or more clock hours 267 
of pathology to have the same level of “plus-ness” as a zone I eye. This may explain why 268 
multiple studies have found approximately 10% of the time clinicians document that they are 269 
treating outside published guidelines based on clinical judgment, most commonly zone II stage 3 270 
without plus.25,26 Clinician should be aware of this finding to minimize adverse anatomic 271 
outcomes that can occur, such as vascular straightening even in the absence of retinal detachment. 272 
Since the subjective interpretation of plus disease was a hidden bias within the ETROP study, 273 
and it has become clear that this is interpreted so widely in the real world, without prospective 274 
adoption of a more granular clinical scale, or objective assessment of vascular severity, it is not 275 
clear how to ensure consistent interpretation of evidence-based medicine over time.  276 
There are several limitations to this analysis. First, although we have proposed two 277 
methods for the development of a vascular severity score, one objective (based on deep learning), 278 
and one subjective (based on comparison to standard images), these methods were not designed 279 
to produce identical results especially at the low and high ends of the scale. The primary reason 280 
for this is that the current deep learning system was derived from a 3-level plus disease scale and 281 
thus has the same limitation as the current system (i.e. it was not calibrated to determine 282 
differences within a given plus disease level). Development of a larger database of clinician-283 
labeled 1-9 images would enable training of a pure deep learning model either as a classification 284 
(to identify the most likely 1-9 class label) or a regression (continuous) model. Second, the deep 285 
learning model here was trained with plus disease reference standard labels from some of the 286 
same images as presented in the ICROP comparison dataset. This means that the highly 287 
significant association with plus disease is not surprising. However, it does not affect the 288 
interpretation of the relationship between zone, stage, and extent which were not part of the 289 
training.  Third, the deep learning system was trained only on RetCam images and would need to 290 
be retrained and validated on other camera systems, and across a variety of image quality. 27 291 
Fourth, all of the images in the training set were from a North American population and thus the 292 
translatability of this scale to other populations needs to be evaluated. Fifth, the ROP graders in 293 
this study are all collaborators and may demonstrate higher inter-rater agreement than a random 294 
sample of clinicians, though it suggests that, with training, agreement on a 1-9 scale is possible. 295 
Taken together, these findings demonstrate how a more granular vascular severity scale 296 
for ROP, such as the one proposed, may complement the existing body of knowledge that 297 
multiple clinical trials have generated using the current ICROP classification. Adopting such a 298 
scale may facilitate more precise monitoring of disease progression and enable future clinical 299 
trials that rely on objective metrics of ROP disease severity. These results further demonstrate 300 
how the rise of deep learning systems may have clinical benefits beyond image-based diagnosis 301 
for ROP. Specifically, as more of medicine is moving towards objective and quantitative 302 
diagnosis, the use of deep learning to generate objective disease severity scales may be a 303 
generalizable methodology that works in many of the diseases where deep learning is currently 304 
being applied.  305 
 306 
 307 
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  385 
Figure Legends 386 
Figure 1: Representative images from each 1-9 label. These images were selected based on 387 
the reference standard diagnosis with 1-3 having a diagnosis of no plus, 4-6 having a diagnosis 388 
of pre-plus, and 7-9 having a diagnosis of plus, but with varying degrees of vascular severity 389 
within each class.  390 
 391 
Figure 2: Relationship between deep learning (DL) derived vascular severity score and 392 
zone, stage, extent and plus classifications. A higher vascular severity score (1-9) was 393 
associated with higher disease stage and extent of stage 3. For a given stage and extent of stage 3, 394 
the vascular severity score was higher in zone I compared with zone II or III.  395 
 396 
Figure 3. Disease progression using current versus proposed classification. Two eyes that 397 
were included in the dataset and were noted to have disease progression over time. In both (A) 398 
and (B), disease progression is noted using the 1-9 scale that was not reflected in a change in 399 
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